Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: A Phase 1 Nonrandomized Controlled Trial.
作者信息
Ahmed Kamran A, Kumthekar Priya U, Pina Yolanda, Kim Youngchul, Vogelbaum Michael A, Han Hyo S, Forsyth Peter A
机构信息
Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.
Department of Neuro-Oncology, Northwestern University, Chicago, Illinois.
出版信息
JAMA Oncol. 2024 Jul 1;10(7):984-986. doi: 10.1001/jamaoncol.2024.1299.
Abstract
摘要
相似文献
1
Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: A Phase 1 Nonrandomized Controlled Trial.放射治疗后鞘内注射曲妥珠单抗-帕妥珠单抗治疗ERBB2阳性乳腺癌软脑膜疾病：一项1期非随机对照试验
JAMA Oncol. 2024 Jul 1;10(7):984-986. doi: 10.1001/jamaoncol.2024.1299.
2
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.曲妥珠单抗和帕妥珠单抗联合吉西他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者的疗效和安全性：一项 2 期临床试验。
JAMA Netw Open. 2019 Nov 1;2(11):e1916211. doi: 10.1001/jamanetworkopen.2019.16211.
3
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.帕妥珠单抗联合曲妥珠单抗联合或不联合化疗序贯恩美曲妥珠单抗治疗人表皮生长因子受体 2 阳性转移性乳腺癌：一项随机临床试验的二次分析。
JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909.
4
Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer.鞘内注射曲妥珠单抗和噻替派治疗乳腺癌软脑膜转移
Ann Oncol. 2009 Apr;20(4):792-5. doi: 10.1093/annonc/mdp019. Epub 2009 Feb 17.
5
High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.大剂量鞘内注射曲妥珠单抗治疗HER-2过表达乳腺癌继发软脑膜转移
Ann Oncol. 2008 Nov;19(11):1978-80. doi: 10.1093/annonc/mdn654. Epub 2008 Oct 9.
6
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.在亚洲，曲妥珠单抗、帕妥珠单抗和多西他赛治疗早期或局部晚期 ERBB2 阳性乳腺癌患者的疗效、安全性和耐受性：PEONY 三期随机临床试验。
JAMA Oncol. 2020 Mar 1;6(3):e193692. doi: 10.1001/jamaoncol.2019.3692. Epub 2020 Mar 12.
7
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.T-DM1 治疗 HER2 阳性转移性乳腺癌脑膜和脑转移患者的疗效：系统治疗的新方向-病例报告及文献复习。
BMC Cancer. 2018 Jan 25;18(1):97. doi: 10.1186/s12885-018-3994-5.
8
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial.ERBB2 乳腺癌化疗前瘤内树突状细胞对肿瘤微环境的改变：一项非随机临床试验
JAMA Oncol. 2025 Feb 1;11(2):119-127. doi: 10.1001/jamaoncol.2024.5371.
9
Real-world clinical study of trastuzumab biosimilar (Zercepac) and pertuzumab (Perjeta) in combination with chemotherapy for neoadjuvant treatment of HER-2-positive breast cancer.曲妥珠单抗生物类似药（Zercepac）和帕妥珠单抗（Perjeta）联合化疗用于HER-2阳性乳腺癌新辅助治疗的真实世界临床研究。
Asian J Surg. 2024 Jul;47(7):3225-3228. doi: 10.1016/j.asjsur.2024.03.063. Epub 2024 Mar 23.
10
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.曲妥珠单抗和帕妥珠单抗固定剂量组合用于皮下注射联合化疗治疗 HER2 阳性早期乳腺癌（FeDeriCa）：一项随机、开放标签、多中心、非劣效性、III 期研究。
Lancet Oncol. 2021 Jan;22(1):85-97. doi: 10.1016/S1470-2045(20)30536-2. Epub 2020 Dec 21.
引用本文的文献
1
Intrathecal pemetrexed for newly diagnosed leptomeningeal metastases: a multicenter, open-label, phase I/II study.鞘内注射培美曲塞用于新诊断的柔脑膜转移：一项多中心、开放标签的I/II期研究。
J Neurooncol. 2025 Jul 23. doi: 10.1007/s11060-025-05160-4.
2
Drug treatment of breast cancer brain metastases: progress and challenges.乳腺癌脑转移的药物治疗：进展与挑战
Discov Oncol. 2025 Jun 7;16(1):1025. doi: 10.1007/s12672-025-02820-9.
3
Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.脑脊液分析及软脑膜转移瘤的治疗意义
J Neurooncol. 2025 Mar;172(1):31-40. doi: 10.1007/s11060-024-04902-0. Epub 2024 Dec 20.
4
Leptomeningeal metastatic disease: new frontiers and future directions.软脑膜转移瘤：新前沿与未来方向。
Nat Rev Clin Oncol. 2025 Feb;22(2):134-154. doi: 10.1038/s41571-024-00970-3. Epub 2024 Dec 9.
Zotero 插件